Irinotecan Hydrochloride Seacross Pharmaceuticals (Irinotecan Hydrochloride Trihydrate)

Irinotecan is a prodrug that is metabolized to SN‑38, which inhibits topoisomerase I. This enzyme normally relieves torsional strain during DNA replication. By blocking topoisomerase I, SN‑38 prevents DNA strand re‑ligation, causing DNA breaks that lead to cancer cell death.

The specific dose of Irinotecan Hydrochloride is determined by the prescribing oncologist based on factors such as cancer type, disease stage, patient weight, and overall health. Dosage regimens are individualized and should follow the prescriber’s instructions.

Irinotecan’s safety in pregnancy and lactation is not well established. It is generally avoided unless the potential therapeutic benefit outweighs the possible risks to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Irinotecan belongs to the topoisomerase I inhibitor class, offering a distinct mechanism from fluoropyrimidines (e.g., 5‑FU) and oxaliplatin. It is often combined with these agents to enhance efficacy. Compared with monotherapy, Irinotecan‑based combinations typically provide higher response rates but may increase the risk of specific toxicities such as diarrhea and neutropenia.

Irinotecan Hydrochloride for injection should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. Follow aseptic techniques when reconstituting and administering the medication.

Irinotecan is given intravenously, typically as an infusion over 30 to 90 minutes depending on the protocol. The infusion is performed by qualified healthcare professionals in a clinical setting, with monitoring for infusion‑related reactions and supportive care as needed.

The most serious risks include severe neutropenia, febrile neutropenia, and life‑threatening diarrhea (colitis). Patients should be monitored closely for signs of infection, fever, or persistent gastrointestinal symptoms, and prompt medical intervention is required if these events occur.

Irinotecan is contraindicated in patients with known hypersensitivity to the drug or its components. It should also be avoided in individuals with severe hepatic impairment, uncontrolled infections, or those who are pregnant unless the potential benefit justifies the risk.